Enavatuzumab (Anti-TNFRSF12A / TWEAKR / CD266)
Enavatuzumab (Anti-TNFRSF12A / TWEAKR / CD266) is a humanized monoclonal antibody directed against the tumor necrosis factor-like weak inducer of apoptosis receptor (TWEAKR) with potential antineoplastic, immunomodulating and antiangiogenic activities. MW : 150 kD.
| Supplier | Selleck Chemicals |
|---|---|
| Product # | A2697 |
| Sku # | A2697-1mg*5 |
| Pricing | 1mg*5, $970.00 |